The general direction of medical reform in the second half of the year has been determined, how pharmaceutical companies "bear the burden" forward

In July this year, the state issued a notice on the key tasks of deepening the reform of the medical and health system in the second half of 2020 (the "Notice"), indicating the direction for the reform of the medical and health system in the second half of the year.
industry believes that the "Notice" on the public health system has been systematically designed, especially three of the highlights, will be in the next time in all areas of the pharmaceutical industry have a significant impact.
The general direction of medical reform in the second half of this year has been determined, how pharmaceutical companies "bear the burden" forward (photo source: pharmaceutical network) in the second half of the medical reform has three bright spots from the specific content of the document, the direction of medical reform in the second half of this year has been determined, of which three bright spots are very noteworthy.
"Notice" clearly proposed that the drug supplies procurement policy will be improved.
expand the scope of centralized procurement and use of drug varieties by national organizations in an orderly manner, and carry out a pilot project on centralized procurement of high-value medical supplies.
to encourage medical insurance agencies to settle drug purchases directly with pharmaceutical production or circulation enterprises.
, the industry believes that, although the next stage, Chinese medicine oral preparations, insulin, biosypolytic drugs are more likely to be included in the collection.
, but in general, with the volume of procurement of reverse drugs, consumables price reduction trend is also very obvious.
this form, the pharmaceutical industry's industrial purification and upgrading, backward production capacity elimination will continue and strengthen.
, the Notice clearly proposed to promote the revitalization and development of Chinese medicine.
put forward that in general hospitals, infectious disease hospitals, specialized hospitals and other efforts to promote the combination of Chinese and Western medicine medical model, accelerate the construction of Chinese medicine evidence-based medical center and other content.
this in the industry, will further stimulate the Chinese medicine industry's huge market space, but it is important to note that the relevant enterprises in the face of greater opportunities for development, but also will face greater challenges and more stringent controls.
In addition, the Notice also made clear the four key tasks of "improving the level of basic medical security, promoting the reform of medical insurance payment methods, strengthening the management of medical insurance funds, improving the regulatory mechanism, and accelerating the development of commercial health insurance".
this means that in the future the health care sector will have more reasonable planning of health insurance funds, which the industry believes may lead to the pharmaceutical industry to face more stringent, standardized health care reform policies, the pharmaceutical industry reshuffle will become more serious.
drug companies how to deal with the general trend of medical reform, the new medical reform situation, many pharmaceutical companies are facing the situation of survival of the fittest.
how to recognize the situation and deal with the changes in the pharmaceutical industry is a factor for pharmaceutical companies to consider.
, how exactly should pharmaceutical companies make corresponding changes? Industry insiders believe that in order to maintain market share, we must ensure product quality under the premise, not only to achieve "time-grabbing, cost control", but also to achieve "alternative, re-research and development."
fact, combined with the health care reform policy in recent years, the country's determination to control fees reform is very obvious.
such as DRG, volume procurement, and consistent evaluation are further undermining the pricing power of the drug bidding department, as well as the prescription drug capacity of doctors.
drug companies, if they want to retain market share, they must adapt to the current situation.
, in order to ensure the quality of drugs under the premise of price reduction is the main way out.
the long run, pharmaceutical companies must change the past simple and crude sales model, increase the research and development talent pool and research and development investment is the right way.
in short, the policy is changing, the industry is changing, the pattern is changing in the environment, the model and mechanism of pharmaceutical companies must also change with it.
from skill to internal function, from imitation to innovation, from marketing to diversification.
, under the environment of medical reform, pharmaceutical enterprises are no longer pure products, talent competition.
In the mode of competition will determine the success or failure of enterprises, pharmaceutical enterprises only in accordance with the actual situation, grasp the fundamental management, in the change of development, in the development of growth, in order to better and longer-term development.